<DOC>
	<DOCNO>NCT00978432</DOCNO>
	<brief_summary>The purpose study evaluate response , safety tolerability subject receive investigational drug , RAD001 LBH589 . Subjects Part 1 receive one drug four cycle follow 4 cycle second drug unless achieve complete remission . Subjects complete remission may receive 6 cycle study drug receive next study drug evidence disease progression . Subjects Part 2 receive drug together least 2 cycle 13 tolerate .</brief_summary>
	<brief_title>Epigenetic Modulation Relapsed/Refractory Diffuse Large B-Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description>This prospective , non-randomized , un-blinded phase 2 efficacy trial use mechanistic target rapamycin ( mTOR ) inhibitor histone deacetylase ( HDAC ) inhibitor epigenetic targeted therapy . Subjects receive RAD001 LBH589 give two thirteen , 28-day cycle . Subjects assess disease status 2 cycle every 4 cycle . Subjects progressive disease stop 2 cycle . Subjects stable disease well le may receive 13 cycle . LBH589 give 40mg study first open change 20mg po shortly thereafter . LBH589 take day M/W/F . RAD001 give 10mg po daily Part 1 . In Part 2 , LBH589 give 15mg RAD001 give 7.5mg . Treatment administer outpatient basis . Patients follow 2 year completion therapy progression disease death .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1. de novo transform Diffuse large B cell nonHodgkin lymphoma ( DLBCL ) . DLBCLlike lymphoma allow : EpsteiBarr virus ( EBV ) + DLBCL elderly , DLBCL chronic inflammation , Primary cutaneous DLBCL , leg type , B cell lymphoma unclassifiable DLBCL Burkitt lymphoma , B cell lymphoma unclassifiable large B cell lymphoma classical Hodgkin lymphoma , Anaplastic lymphoma kinase ( ALK ) + large B cell lymphoma , T cell histiocyte rich large B cell lymphoma Primary mediastinal B cell lymphoma Follicular grade 3 B cell lymphoma 2 . Refractory relapse disease &gt; /= 1 prior treatment regimen : include autologous stem cell transplant unless patient refuse ineligible . 3 . Age &gt; 18 year old 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 . 5 . Measurable evaluable disease physical exam , radiographs bone marrow involvement 6 . Frozen tumor paraffinembedded sample available . 7 . 34 core fresh/freshfrozen biopsy specimens available . Leukapheresis may do patient leukocytosis . 8 . Laboratory Values per protocol . 1 . Laboratory Values Grade 3 hyperlipidemia ( Serum cholesterol &gt; 400mg/dl serum triglyceride &gt; 5 x ULN ) Serum Glucose &gt; 250mg/dl &gt; /= 2 check 2 separate day Diabetics accept sugar control 2 . Unlimited prior chemotherapy regimen , however : No prior exposure RAD001 LBH589 drug target mTOR ( sirolimus , temsirolimus , etc ) HDAC ( vorinostat ) No valproic acid study 5 day precede start first drug No chemotherapy , biologics immunotherapy &lt; 2 week registration ( 6 week last received bischloroethylnitrosourea ( BCNU ) mitomycin C ) . Subjects must recover therapyrelated nonhematological toxicity &lt; grade 1 baseline start &gt; grade 1 toxicity . No time limit radiation prior registration . No radioimmunotherapy &lt; 2 month prior registration . Subjects must recover therapyrelated toxicity &lt; grade 1 baseline start &gt; grade 1 toxicity . No prior allogeneic stem cell transplantation unless allogeneic engraftment &lt; 2 % . Subjects receive chronic , systemic treatment corticosteroid = &gt; 20mg prednisone per day . Subjects receive replacement adrenal insufficiency allow . Topical inhale corticosteroid allow . 3 . History primary malignancy &lt; 3 year ago , except inactive basal , squamous cell carcinoma skin superficial melanoma require excision , prostate cancer prostate specific antigen ( PSA ) stable &gt; /=3 month , carcinoma situ cervix . 4 . Major surgery &lt; 4 week Minor surgery &lt; 2 week registration . Subjects must recover toxicity &lt; grade 1 baseline start &gt; grade 1 toxicity . 5 . Investigational drug &lt; 4 week prior registration . 6 . Impaired Cardiac Function per protocol . 7 . Pregnant breastfeeding female adult reproductive potential use effective birth control 8 . Diffusing capacity transfer factor lung carbon monoxide ( DLCO ) &lt; 40 % test ( per protocol ) . 9 . Impaired lung function : O2 saturation 88 % less rest room air Pulse Oximetry . 10 . Immunization live attenuate vaccine &lt; 1 week study entry 11 . Impaired GI function GI disease may alter absorption RAD001 LBH589 12 . Concurrent severe &amp; /or uncontrolled medical condition 13 . Medications risk prolong QT interval induce torsade de point interact LBH589 RAD001 may use per protocol . 14 . Active bleeding tendency 15 . Positive HIV . 16 . Positive Hepatitis C virus ( HCV ) . 17 . History noncompliance medical regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>NHL</keyword>
	<keyword>DLBCL</keyword>
	<keyword>recurrent</keyword>
	<keyword>refractory</keyword>
	<keyword>de novo</keyword>
</DOC>